ULK3 and Miyoshi myopathy: In vivo studies with ULK3 ablated MM cells showed delayed disease progression and prolonged survival, demonstrating ULK3’s role in MM, while resistance to MA9 in ULK3 KO cells confirmed the inhibitor’s on-target activity and therapeutic potential.